<DOC>
	<DOCNO>NCT01306617</DOCNO>
	<brief_summary>The purpose study evaluate antiviral activity , safety , pharmacokinetics ABT-450 ritonavir ( ABT-450/r ) dose combination ABT-333 ( also know dasabuvir ) ribavirin ( RBV ) treatment-naïve non responder participant genotype 1 chronic hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety , Pharmacokinetics ABT-450 With Ritonavir ( ABT-450/r ) When Given Together With ABT-333 Ribavirin ( RBV ) Treatment-Naïve Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus ( HCV ) Infection</brief_title>
	<detailed_description>This phase 2a multicenter , open-label , sequential , 3-arm , combination treatment study regimen ABT-450/r/ABT-333 , ribavirin ( RBV ) hepatitis C virus ( HCV ) genotype 1-infected treatment-naïve participant previous non-responders pegylated interferon ( pegIFN ) /RBV treatment .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Chronic hepatitis C virus ( HCV ) Treatment naive , null partial responder previous treatment peginterferon ribavirin Males females 1865 year old Body mass index 18 &lt; 35 kg/m^2 Females must postmenopausal least 2 year surgically sterile Cirrhosis extensive bridging fibrosis History cardiac disease Positive screen certain drug alcohol Abnormal laboratory result Significant sensitivity drug Positive hepatitis B surface antigen antihuman immunodeficiency virus antibody Use strong cytochrome P450 3A ( CYP3A ) , cytochrome P450 2C8 ( CYP2C8 ) , organic anion transport polypeptide 1B1 ( OATP1B1 ) enzyme inducer inhibitor within 1 month dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>